Results 101 to 110 of about 11,994,000 (257)

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Evaluation of the World Bank Group’s Support for Electricity from Renewable Energy Resources, 2000-2017

open access: yes, 2020
The Clean Energy Transition—the pathway for decarbonizing global energy—is essential to foster inclusive and sustainable growth while addressing climate change.
Independent Evaluation Group
core   +1 more source

Ketoacidosis as unexpected adverse reaction SGLT2 inhibitor

open access: yesБезопасность и риск фармакотерапии, 2018
Inhibitors of the sodium-glucose cotransporter-2 SGLT2 is a new class of hypoglycemic drugs. This article presents the information on FDA reports (2013-2015) and AIS (May 2015 - February 2016) on the risk of new adverse reaction - ketoacidosis ...
T. M. Bukatina   +7 more
doaj  

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

open access: yesMolecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis   +3 more
wiley   +1 more source

Cell cultures in replacement therapy

open access: yesБиопрепараты: Профилактика, диагностика, лечение, 2018
Cell replacement therapy is one of the top priority areas of modern medicine, which is aimed at restoring the structure and functions of damaged tissues by transplanting cells grown in vitro .
E. M. Petruchuk   +7 more
doaj  

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

open access: yesMolecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder   +10 more
wiley   +1 more source

First available biosimilar monoclonal antibodies

open access: yesБиопрепараты: Профилактика, диагностика, лечение, 2018
The review deals with the issues related to the special aspects of the development of the first available similar biopharmaceuticals/biological analogues («biosimilars») based on monoclonal antibodies.
Zh. I. Avdeeva   +7 more
doaj  

[Advertising or information in ophthalmology? : Scientific evaluation of a YouTube sample]. [PDF]

open access: yesOphthalmologe, 2021
Schrenk K   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy